Ocriplasmin
- Generic Name
- Ocriplasmin
- Brand Names
- Jetrea
- Drug Type
- Biotech
- CAS Number
- 1048016-09-6
- Unique Ingredient Identifier
- 7V6HE3DM5A
- Background
Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
- Indication
Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
- Associated Conditions
- Symptomatic Vitreomacular Adhesion (VMA)
Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2011-09-27
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 30
- Registration Number
- NCT00996684
- Locations
- 🇺🇸
Jules Stein Eye Institute/UCLA, Los Angeles, California, United States
Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 24
- Registration Number
- NCT00986362
- Locations
- 🇺🇸
Associated Retina Consultants, Royal Oak,, Michigan, United States
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
- Conditions
- Exudative Age-Related Macular DegenerationFocal Vitreomacular Adhesion
- Interventions
- Drug: Sham injection
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 100
- Registration Number
- NCT00913744
- Locations
- 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Retinal Consultants of Houston,, Houston,, Texas, United States
🇬🇧Moorfields Eye Hospital, London, United Kingdom
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 326
- Registration Number
- NCT00798317
- Locations
- 🇺🇸
Retina Specialists, Pensacola, Florida, United States
🇺🇸Black Hils regional Eye Institute, Rapid City, South Dakota, United States
🇺🇸Scheie Eye Institute, Penn Eye Care, Philadelphia,, Pennsylvania, United States
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 326
- Registration Number
- NCT00781859
- Locations
- 🇺🇸
Retina Vitreous Associate Medical Group, Beverly Hills, California, United States
🇺🇸VMR Institute, Huntington Beach, California, United States
🇺🇸Southern California Desert Retina Consultants, Palm Springs, California, United States
A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 60
- Registration Number
- NCT00435539
- Locations
- 🇧🇪
ZNA OCMW Antwerpen, Antwerpen, Belgium
🇧🇪University Hospital of Ghent, Ghent, Belgium
🇧🇪Universitaire Ziekenhuizen K.U.Leuven, Leuven, Belgium
Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 6
- Registration Number
- NCT00428129
- Locations
- 🇮🇪
Section of Interventional Radiology, Department of Radiology, University College Hospital, Newcastle Road, Galway, Co Galway, Ireland
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
- Conditions
- Vitrectomy
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 125
- Registration Number
- NCT00412958
- Locations
- 🇺🇸
Mailing add: New England Eye Center - Tufts, Boston, Massachusetts, United States
🇺🇸Associated Retinal Consultants, P.C., Royal Oak, Michigan, United States
🇺🇸Allegheny Ophthalmic & Orbital Associates, P.C., Pittsburgh, Pennsylvania, United States
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 51
- Registration Number
- NCT00412451
- Locations
- 🇪🇸
Instituto Technologico de Oftalmologia SL., Santiago de Compostela, Spain
🇳🇱Academic Hospital Groningen, Groningen, Netherlands
🇳🇱Het Oogziekenhuis Rotterdam, Rotterdam, Netherlands
Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 2
- Registration Number
- NCT00123266
- Locations
- 🇩🇪
Universitatsklinikum Freiburg, Freiburg, Germany
🇩🇪Universitätsklinikum Erlangen, Erlangen, Germany
🇩🇪HSK Dr. Horst Schmidt Hospital, Wiesbaden, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.